Patent classifications
C07C253/30
Functionalized choline chloride ionic liquid, preparation method thereof and use in electrochemical energy storage device
The present invention discloses a process for preparing a functionalized choline chloride ionic liquid as defined in formula (I), and thereof use in an electrochemical energy storage device, as an electrolyte solution or an additive for a lithium ion battery and a supercapacitor. The ionic liquid electrolyte material has better biocompatibility, flame retardance, high ionic conductivity, low viscosity, and wide electrochemical window. ##STR00001## wherein R.sup.1 is selected from the group consisting of: (CH.sub.2═CH—(CH.sub.2).sub.n)—, CN(CH.sub.2).sub.n—, or R.sup.2.sub.3Si—; R.sup.2 is selected from CH.sub.3—(CH.sub.2).sub.m—, n is an integer selected from 1 to 3, m is an integer selected from 0 to 2; or one of R.sup.2 is (CH.sub.3).sub.3Si—O—. Anion A in Formula I is selected from the group consisting of: Cl.sup.−, Br.sup.−, I.sup.−, BF.sub.4.sup.−, NO.sub.3.sup.−, SO.sub.4.sup.2−, CF.sub.3COO.sup.−, CF.sub.3SO.sub.3.sup.−, (CF.sub.3SO.sub.2).sub.2N.sup.−, PF.sub.6.sup.−, BF.sub.2C.sub.2O.sub.4.sup.−, or B(C.sub.2O.sub.4).sub.2.sup.−.
Fluorine-containing complex compound, and production method for fluorine-containing organic compound employing same
An object of the present invention is to enable the synthesis of various fluorine-containing compounds having an organic group at both terminals of their tetrafluoroethylene structure (—CF.sub.2—CF.sub.2—). The present invention provides a fluorine-containing complex compound including a fluorine-containing organic metal compound represented by formula (1a):
R.sup.1—CF.sub.2—CF.sub.2-M.sup.1 (1a)
wherein M.sup.1 is a metal selected from the group consisting of copper, zinc, nickel, iron, cobalt, and tin; and R.sup.1 represents an organic group, and at least one ligand selected from the group consisting of pyridine ring-containing compounds and phosphines.
Fluorine-containing complex compound, and production method for fluorine-containing organic compound employing same
An object of the present invention is to enable the synthesis of various fluorine-containing compounds having an organic group at both terminals of their tetrafluoroethylene structure (—CF.sub.2—CF.sub.2—). The present invention provides a fluorine-containing complex compound including a fluorine-containing organic metal compound represented by formula (1a):
R.sup.1—CF.sub.2—CF.sub.2-M.sup.1 (1a)
wherein M.sup.1 is a metal selected from the group consisting of copper, zinc, nickel, iron, cobalt, and tin; and R.sup.1 represents an organic group, and at least one ligand selected from the group consisting of pyridine ring-containing compounds and phosphines.
Fluorine-containing complex compound, and production method for fluorine-containing organic compound employing same
An object of the present invention is to enable the synthesis of various fluorine-containing compounds having an organic group at both terminals of their tetrafluoroethylene structure (—CF.sub.2—CF.sub.2—). The present invention provides a fluorine-containing complex compound including a fluorine-containing organic metal compound represented by formula (1a):
R.sup.1—CF.sub.2—CF.sub.2-M.sup.1 (1a)
wherein M.sup.1 is a metal selected from the group consisting of copper, zinc, nickel, iron, cobalt, and tin; and R.sup.1 represents an organic group, and at least one ligand selected from the group consisting of pyridine ring-containing compounds and phosphines.
Substituted hydroxystilbenes and their therapeutic applications
It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.
Substituted hydroxystilbenes and their therapeutic applications
It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.
Substituted hydroxystilbenes and their therapeutic applications
It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.
METHOD FOR THE DISTILLATIVE PURIFICATION OF EDA
The present invention relates to a process for purifying ethylenediamine (EDA) by distillation, wherein the process comprises the steps a) and b). In step a), a mixture (G1) comprising water, EDA and N-methylethylenediamine (N-MeEDA) is fed into a distillation apparatus (D1), and the major part of the water comprised in the mixture (G1) is separated off overhead at a pressure of greater than 4.8 bara. From the bottom of (D1), the water-enriched mixture (G2) is fed into a distillation apparatus (D2) in step b). At the top of (D2), the major part of the N-MeEDA is distilled off. The stream (S3) obtained from the bottom of (D2) comprises EDA, with the components water and N-MeEDA comprised in the mixture (G1) having been largely or completely removed. Further distillation steps can optionally be carried out in order to obtain pure EDA, for example when diethylenetriamine (DETA) is additionally comprised in the mixture (G1). If ammonia is additionally comprised in the mixture (G1), an ammonia removal is preferably additionally carried out before carrying out the step a) in the process of the invention.
METHOD FOR THE DISTILLATIVE PURIFICATION OF EDA
The present invention relates to a process for purifying ethylenediamine (EDA) by distillation, wherein the process comprises the steps a) and b). In step a), a mixture (G1) comprising water, EDA and N-methylethylenediamine (N-MeEDA) is fed into a distillation apparatus (D1), and the major part of the water comprised in the mixture (G1) is separated off overhead at a pressure of greater than 4.8 bara. From the bottom of (D1), the water-enriched mixture (G2) is fed into a distillation apparatus (D2) in step b). At the top of (D2), the major part of the N-MeEDA is distilled off. The stream (S3) obtained from the bottom of (D2) comprises EDA, with the components water and N-MeEDA comprised in the mixture (G1) having been largely or completely removed. Further distillation steps can optionally be carried out in order to obtain pure EDA, for example when diethylenetriamine (DETA) is additionally comprised in the mixture (G1). If ammonia is additionally comprised in the mixture (G1), an ammonia removal is preferably additionally carried out before carrying out the step a) in the process of the invention.
Process for producing substituted amino alcohols
A process for producing a compound of the formula (I) ##STR00001##
involves at least reacting a compound of the formula (II) ##STR00002##
with hydrogen and water in the presence of at least one homogeneous transition metal catalyst TMC 1.